Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Juul reaches $439 million settlement over marketing to children

Juul Labs Inc. reached an agreement in principle to pay $438.5 million to 33 states to resolve a two-year bipartisan probe into the e-cigarette manufacturer’s marketing and sales practices, particularly claims that it marketed addictive nicotine products to children.

Tribune News Service

Juul will pay nearly $440 million to settle states' investigation into teen vaping

The electronic cigarette maker has agreed to settle a two-year investigation by 33 states and Puerto Rico into the marketing of its vaping products, which have been blamed for a surge in teen vaping.

WEKU

Juul to pay nearly $440M to settle states' teen vaping probe

Electronic cigarette maker Juul Labs will pay nearly $440 million to settle a multi-state investigation into its vaping products, which have long been blamed for sparking a national surge in teen vaping

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Stopgap funding bill set to dominate September agenda - Roll Call

Lawmakers will wrestle with a White House request for $47.1 billion in emergency funds and the need to avert a partial government shutdown.

Roll Call

Unions call on Truss to crack down on sexual harassment in Westminster

Prospect and FDA say new leadership brings a fresh opportunity to restore confidence that Parliament is a safe place to work.

The Independent UK

NERV Stock Is on the Move, but Is It a Buy?

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings growth prospects, the stock has gained more than 260% over the past month because the company submitted an NDA for…

StockNews.com

The man who breeds tens of thousands of leeches for the NHS from a tiny Welsh farm

Carl Peters-Bond, from Biopharm Leeches in Hendy, is one of just two FDA registered leech farmers in the world

Wales Online

Read news from The Economist, FT, and more,
with one subscription

Food expiration dates are confusing

A food safety researcher explains another way to know what’s too old to eat

Salon

FDA still skeptical of ALS drug ahead of high-stakes meeting

The U.S. Food and Drug Administration has posted another negative review of a closely watched drug for the deadly neurodegenerative disease ALS

The Independent UK

3 Stocks With Decades of Dividend Payments

Concerns over high inflation, the Fed’s hawkish stance to control it, and an economic slowdown have led to immense stock market volatility. Therefore, it could be wise to invest in stocks with decades of dividend-paying history, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Becton, Dickinson and Company (BDX),…

StockNews.com

Does Paxlovid cause Covid rebound?

US president and first lady have both reported relapses after using drug to treat coronavirus

The Independent UK

EXPLAINER: Should you get a new COVID booster? If so, when?

New COVID-19 boosters targeting today’s most common omicron strains should begin arriving within days

The Independent UK

Where Is the Republican Plan To Reform Public Health?

The GOP has understandably cast Anthony Fauci as a villain, but there are few plans to overhaul public health bureaucracies.

Reason

"Game-changer" Paxlovid turns into pandemic enigma

Paxlovid goes from COVID game-changer to pandemic enigma

Axios

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

CDC advisers endorse booster shots that target omicron for Americans 12 and up

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

WEKU

CDC recommends new booster shots to fight omicron

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

StockNews.com

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Want to Lower Your Risk? Give These 3 Safe Stocks a Try

The uncertainty surrounding the market and the economy because the Federal Reserve signaled to continue hiking interest rates is making investors seek low-risk investments. Given lower volatility and attractive dividend payments, Johnson & Johnson (JNJ), CVS Health (CVS), and Summit Financial Group (SMMF) could be good candidates to consider on…

Benzinga

Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics

Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.

The Independent UK

CDC advisers weigh who needs updated COVID booster and when

Government advisers are debating who should should get new updated COVID-19 boosters and when

The Conversation

Will omicron-specific booster shots be more effective at combating COVID-19? 5 questions answered

On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…

Benzinga

Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash…

Wall Street Journal

Los Angeles Times

Michael Hiltzik: In blow to public health, judge tosses FDA lawsuit targeting a clinic offering unproven stem cell treatments

A federal judge in Riverside, California, declared a stem cell treatment firm operating in the state to be exempt from Food and Drug Administration regulations, opening the door to the further proliferation of clinics offering therapies the FDA says are scientifically unproven and potentially dangerous.

Chicago Sun-Times

New COVID-19 booster shots could be available in Chicago after Labor Day

The FDA today authorized the new booster, which could arrive as early as next week in Chicago, where nearly 2 million residents are expected to be eligible.

1 … 191 192 193 194

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.